The initial goal of precision psychiatry isn't complex machine learning or perfect biomarkers. It's about systematically collecting basic, meaningful data—like cognitive function—that we already know correlates with treatment outcomes. This simple act of consistent measurement provides a powerful foundation for better understanding patients.

Modern psychiatry defines disorders by a checklist of symptoms (e.g., via the DSM), treating the syndrome itself as the disease. This is unlike the rest of medicine, which views symptoms like a cough as signals of various underlying causes. This flawed approach has stalled progress by focusing on labels instead of mechanisms.

Moving beyond Freudian theory and the "chemical imbalance" hypothesis, "Psychiatry 3.0" views mental illness as a problem of brain circuitry. Treatments like TMS and psychedelics show that recalibrating these circuits can rapidly resolve symptoms, framing conditions like depression as correctable rather than a permanent deficit.

During deep brain stimulation (DBS) for movement disorders, accidentally stimulating nearby brain regions can cause brief side effects like laughter or panic. Neurosurgeon Dr. Casey Halpern explains these unintended effects are not just errors, but crucial discoveries that have revealed how to therapeutically target circuits for conditions like depression and OCD.

Derek Small argues the breakthrough in neuroscience mirrors oncology's shift from blunt instruments to targeted therapies. By focusing on underlying pathology like synaptic dysfunction and neuroinflammation, rather than just symptoms, developers can achieve biomarker-based approvals and more effective treatments.

Dr. Bolsiewicz reframes major depression not as a purely psychological issue, but as a physiological condition rooted in inflammation. He states with "total clarity" that depression, along with neurodegenerative diseases like Alzheimer's and Parkinson's, is a manifestation of chronic inflammation affecting the brain.

A significant number of medications prescribed for mental illness are also used to treat epilepsy. This overlap suggests that mental disorders and seizure conditions share underlying biological mechanisms, opening the door for non-pharmacological epilepsy treatments like the ketogenic diet to be applied to psychiatry.

Large-scale genetic studies suggest many distinct brain diseases (mania, depression, ADHD, Alzheimer's) are not separate conditions. Instead, they may be different expressions of a single, general genetic susceptibility to brain dysfunction, which researchers call "Factor P".

New single-cell atlases of Parkinson's brains show that biological pathways are activated differently depending on the brain region and disease stage. This adds a critical layer of complexity, implying that a "disease-modifying" drug may need to be targeted to specific cell types at specific times, complicating clinical development.